India is trying to increase its efforts to combat the pandemic, despite rising cases of coronavirus and the threat from the Omicron variant, which is known for causing infection at a faster pace. Two new vaccines were approved by the Centre today, as well as one antiviral drug.
According to Dr. Mansukh Mandaviya’s updates, the two vaccines that have been approved in India for emergency use are Corbevax and Covovax. Covovax, a US-based vaccine manufactured by Novavax, will be manufactured in India by the Serum Institute of India. Biological E Limited, Hyderabad, is producing Corbevax.
This is a significant step in the country’s response to the pandemic. There are currently eight vaccines available, including the previously approved Covishield and Covaxin. The use of the newer vaccines for booster shots is being investigated, but more information will be available once we have fresh updates.
The approval of Molnupiravir, an antiviral drug manufactured in India, is the most important. It will only be available for emergencies to treat high-risk patients. The 200-milligram capsule, which comes in a 200mg capsule, is to be taken orally every 12 hours for five days. There are 40 capsules.
Molnupiravir can be used to treat mild and medium COVID-19 cases. Merck & Co. has licensed the drug to Indian companies, including Cipla Limited and Dr. Reddy’s Laboratories. The company also has a licensing agreement with Sun Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Emcure Pharmaceuticals Ltd, Hetero Labs Ltd, Sun Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.